CSF1R and renal cell carcinoma: Notably, patients with anti-PD-1/PD-L1-resistant advanced RCC achieved clinical benefit in a phase I trial of CSF1R inhibitor (cabiralizumab) and CD40 agonist (sotigalimab) (Weiss et al., 2021).